Scilex Holding SCLX
NASDAQ SCLX
$5.73 -0.07 (-1.21%)
At close: Aug 21, 2026 · 4:00 PM EDT

Scilex Holding (SCLX) Net Income towards Common Stockholders (2020 - 2026)

Scilex Holding (SCLX) posted quarterly Net Income towards Common Stockholders of -$43.3 million for Q1 2026, down 65.91% year-over-year from -$126.9 million in Q1 2025, and down 30.68% quarter-over-quarter from -$33.1 million in Q4 2025.

Scilex Holding (SCLX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Scilex Holding's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$43.3 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 65.91% year-over-year to -$43.3 million; the TTM figure through Mar 2026 stood at -$419.7 million (down 463.25% YoY), while the FY2025 annual figure was -$402.5 million, down 452.81% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$43.3 million, down from -$33.1 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $21.5 million in Q3 2022, with the low at -$257.2 million in Q3 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$26.1 million (2025), against an average of -$41.7 million.
  • Peak annual rise in Net Income towards Common Stockholders reached 7736.6% in 2022, while the deepest fall reached 10688.09% in 2022.
  • Scilex Holding's Net Income towards Common Stockholders stood at -$17.9 million in 2022, then dropped by 19.66% to -$21.4 million in 2023, then soared by 69.81% to -$6.5 million in 2024, then tumbled by 412.57% to -$33.1 million in 2025, then tumbled by 30.68% to -$43.3 million in 2026.
  • Business Quant data shows SCLX's Net Income towards Common Stockholders at -$43.3 million in Q1 2026, -$33.1 million in Q4 2025, and -$257.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 5.53 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 3.62 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 3.26 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 2.51 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -10.50 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -238.00 Mn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 583.63 Mn
10 Scilex Holding 39.22 Mn -73.57 Mn 3.97 Mn -114.73 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -43.27 Mn
Dec 31, 2025 -33.11 Mn
Sep 30, 2025 -257.23 Mn
Jun 30, 2025 -86.06 Mn
Mar 31, 2025 -26.08 Mn
Dec 31, 2024 -6.46 Mn
Sep 30, 2024 -4.39 Mn
Jun 30, 2024 -37.58 Mn
Mar 31, 2024 -24.38 Mn
Dec 31, 2023 -21.40 Mn
Sep 30, 2023 -88.17 Mn
Jun 30, 2023 -26.65 Mn
Mar 31, 2023 -30.75 Mn
Dec 31, 2022 -17.88 Mn
Sep 30, 2022 21.50 Mn
Jun 30, 2022 -17.84 Mn
Mar 31, 2022 -9.14 Mn
Dec 31, 2021 -46.93 Mn
Sep 30, 2021 -281,552.00
Jun 30, 2021 -165,349.00